Impact of Molecular Pathology on Classifying Diffuse Gliomas
Impact of Molecular Pathology on Classifying Diffuse Gliomas
Once assigned to the diffuse glioma category by routine pathological assessment, testing for the IDH1 R132H mutation may be easily conducted using a commercially available antibody test that recognizes the altered epitope. A positive result has high sensitivity and specificity rates for IDH-mut R132H, although reports exist of cross-reactivity with R132L and R132M mutations. A total of 10% to 15% of IDH-mut cases are immunonegative, and such cases can be sent for direct sequencing or hotspot analysis for both IDH1 and IDH2; IDH1 R132C is the most common immunonegative mutation.
Immunohistochemistry
Once assigned to the diffuse glioma category by routine pathological assessment, testing for the IDH1 R132H mutation may be easily conducted using a commercially available antibody test that recognizes the altered epitope. A positive result has high sensitivity and specificity rates for IDH-mut R132H, although reports exist of cross-reactivity with R132L and R132M mutations. A total of 10% to 15% of IDH-mut cases are immunonegative, and such cases can be sent for direct sequencing or hotspot analysis for both IDH1 and IDH2; IDH1 R132C is the most common immunonegative mutation.
Source...